{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Zhang Q"],"pubmed_abstract":["<b>Background:</b> Simmitecan is a potent inhibitor of topoisomerase I with anti-tumor activity. This phase Ib trial was conducted to investigate the safety and anti-tumor effect of simmitecan alone or in combination with other drugs. <b>Methods:</b> Eligible patients with advanced solid tumor had no further standard treatment options. Patients were allocated to receive simmitecan alone, simmitecan in combination with 5-fluorouracil (5-FU)/leucovorin (LV), or simmitecan in combination with thalidomide, 14 days a cycle, until disease progression or unacceptable toxicity occurred. <b>Results:</b> A total of 41 patients were enrolled, with a median age of 55 (range 29-69) years. Among them, 13 patients received simmitecan monotherapy, 10 received simmitecan + 5-FU/LV, and 18 received simmitec"],"journal":["Frontiers in pharmacology"],"pagination":["833583"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9355729"],"repository":["biostudies-literature"],"pubmed_title":["A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor."],"pmcid":["PMC9355729"],"pubmed_authors":["Shen L","Deng T","Li J","Guo W","Yu Q","Ba Y","Zhang Q","Yang F","Yuan J","Cai H","Peng Z","Lu M","Cao Y","Wang X","Liu D","Gong J","Qi C","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor.","description":"<b>Background:</b> Simmitecan is a potent inhibitor of topoisomerase I with anti-tumor activity. This phase Ib trial was conducted to investigate the safety and anti-tumor effect of simmitecan alone or in combination with other drugs. <b>Methods:</b> Eligible patients with advanced solid tumor had no further standard treatment options. Patients were allocated to receive simmitecan alone, simmitecan in combination with 5-fluorouracil (5-FU)/leucovorin (LV), or simmitecan in combination with thalidomide, 14 days a cycle, until disease progression or unacceptable toxicity occurred. <b>Results:</b> A total of 41 patients were enrolled, with a median age of 55 (range 29-69) years. Among them, 13 patients received simmitecan monotherapy, 10 received simmitecan + 5-FU/LV, and 18 received simmitec","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-09T14:11:09.2Z","creation":"2024-11-19T22:29:19.41Z"},"accession":"S-EPMC9355729","cross_references":{"pubmed":["35935841"],"doi":["10.3389/fphar.2022.833583"]}}